Charles River Laboratories CRL Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied at other companies

Medpace Holdings, Inc.MEDP

——

IQVIAIQV

——

DanaherDHR

——

Agilent TechnologiesA

——

Thermo Fisher ScientificTMO

——

WAT

Waters CorporationWAT

——

Other financials

Income statement

See full

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Balance sheet

See full

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Cash flow

See full

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Valuation

See full

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Profitability

See full

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Returns & leverage

See full

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Charles River Laboratories's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied?: Charles River Laboratories (CRL) reported remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied of $702.2M in Q1 2026.
How has Charles River Laboratories's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied changed year-over-year?: Charles River Laboratories's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied decreased by 10.2% year-over-year, from $781.9M to $702.2M.